INTENSITY THERAPEUTICS, INC. INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.
Intratumoral ("IT") treatment, or treatment designed to contain a drug inside a tumor without spreading to the rest of the body, has been an objective of clinicians since discovery of chemotherapeutic agents. The challenge with IT treatment approaches is that a tumor's stromal, high-fat, dense, poorly vascularized, and pressurized microenvironment is incompatible with and does not absorb water-based products. We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments, which have involved injecting aqueous drugs into a tumor without sufficient consideration of the tumor environment. The problem of the incompatibility of the tumor's environment is independent of any water-based drug's mechanism or approach, i.e. the stimulation of an inflammatory response or efforts to attract immune cells into a hostile live tumor. Accordingly, there remains a continued unmet need for the development of direct IT therapies for solid tumors that provide high local killing efficacy coupled with nontoxic systemic anti-cancer effects. We believe we have created a product candidate with the necessary chemistry to overcome this local delivery challenge within the tumor. Evidence shows the mechanism of tumor killing achieved by our drug candidate also leads to systemic immune activation and T-cell repertoire expansion in certain cancers.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $6.8M | $10.5M | $4.8M | $5.1M | — |
| SG&A | $5.2M | $6.1M | $3.5M | $2.4M | — |
| Total operating expenses | $12.0M | $16.6M | $8.3M | $7.5M | — |
| Operating income | -$12.0M | -$16.6M | -$8.3M | -$7.5M | — |
| Interest expense | — | $0 | $305.0K | $82.0K | — |
| Pre-tax income | -$11.6M | -$16.3M | -$10.5M | -$7.6M | — |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$11.6M | -$16.3M | -$10.5M | -$7.6M | — |
| EPS, basic | -8.56 | -29.24 | -1.38 | -2.22 | — |
| EPS, diluted | -8.56 | -29.24 | -1.38 | -2.22 | — |
| Shares, diluted (wtd. avg.) | 1.4M | 556,279 | 8.6M | 3.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $11.9M | $2.6M | $8.6M | $1.3M | $4.5M |
| Total current assets | $12.7M | $3.4M | $15.5M | $1.5M | — |
| Total assets | $14.1M | $4.8M | $17.3M | $1.8M | — |
| Accounts payable | $583.0K | $1.2M | $3.0M | $603.0K | — |
| Total current liabilities | $2.1M | $1.8M | $4.0M | $6.8M | — |
| Total liabilities | $2.2M | $1.9M | $4.1M | $6.9M | — |
| Retained earnings | -$78.4M | -$66.8M | -$50.5M | -$38.7M | — |
| Total equity | $11.9M | $2.9M | $13.2M | -$15.1M | -$8.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.2M | -$15.2M | -$7.2M | -$5.5M | — |
| Stock-based compensation | $2.0M | $3.1M | $1.4M | $1.2M | — |
| Investing cash flow | $0 | $6.4M | -$6.0M | $0 | — |
| Financing cash flow | $18.6M | $2.9M | $20.5M | $2.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001567264-26-000024.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |